CRWV Research Update — August 28, 2026 (Updated)
Updated Thesis
CoreWeave is a specialized GPU cloud provider building AI compute infrastructure, with rapid demand conversion evidenced by $2.575 billion of Q2 2026 revenue, up 112.3% year over year in the most recent quarter, and approximately $104 billion of revenue backlog. Business quality is low despite strong operating execution because the company remains deeply capital intensive, highly leveraged and GAAP unprofitable: TTM gross margin was 67.4%, but TTM operating margin was -3.0%, TTM net margin was -25.4%, ROE was -45.4%, free cash flow per share was -$24.78, and earnings declined 115.5% year over year in the most recent quarter. The historical-multiple regime characterizes the shares as fair, but CRWV is undervalued versus the blended fair value estimate of $129.22 per share, implying 45.0% upside from $89.12, with the principal debate being whether backlog conversion and capacity scale can outpace substantial funding needs and hyperscaler competition.
The investment grade as of this refresh is C — average business quality. Low-tier business, A-tier valuation: $129.22 blended fair value implies 45.0% upside, but $35.6 billion of debt, negative free cash flow and continuing GAAP losses constrain conviction.
Grade Change
In this research cycle, the investment grade for CoreWeave, Inc. Class A Common Stock moved from B to C. Low-tier business, A-tier valuation: $129.22 blended fair value implies 45.0% upside, but $35.6 billion of debt, negative free cash flow and continuing GAAP losses constrain conviction.
Key Metrics at a Glance
- Revenue growth: +112.3% year over year
- Net margin: -25.4%
- Fair value upside: +45.0% to our estimate of $129
Current price: $89.12
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. CoreWeave, Inc. Class A Common Stock remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full CRWV research →](/stocks/CRWV)